Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.
Similar Posts
Disseminated Coccidioidomycosis: Developing Drugs for Treatment
Disseminated Coccidioidomycosis: Developing Drugs for Treatmentwww.usmedschoice.com – 716055 – 10/06/2025
Unapproved New Drugs/MisbrandedAfrica Imports Issues Voluntary Recall of Organic Moringa Leaf Powder Due to Potential Salmonella Contamination
Africa Imports is voluntarily recalling its Organic Moringa Leaf Powder (1 kilogram box) because it may be contaminated with Salmonella, an organism that can cause serious and sometimes fatal infections in young children, the elderly, and individuals with weakened immune systems. Healthy persons infBoothwyn Pharmacy LLC – 710247 – 06/09/2025
Unapproved New Animal Drug/Adulterated/MisbrandedWinder Laboratories, LLC – 718601 – 01/07/2026
CGMP/Finished Pharmaceuticals/AdulteratedQuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/18/2025
Short Title (70 char) QuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025
FEI Number 3012053582
Firm Name QuVa Pharma, Inc
Record Type 483
State TX
Establishment Type Outsourcing Facil